✦ LIBER ✦

Psychiatric-related safety outcomes of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: A phase 3, randomized, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimized study in Europe

✍ Scribed by Lecendreux, M.L.; Dittmann, R.W.; Gasior, M.; Banaschewski, T.; Civil, R.; Bloomfield, R.; Squires, L.; Coghill, D.R.

Book ID: 122399689
Publisher: Elsevier Science
Year: 2012
Tongue: French
Weight: 64 KB
Volume: 60
Category: Article
ISSN: 0222-9617
DOI: 10.1016/j.neurenf.2012.04.685

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weight-related safety outcomes of lisdex

✍ Zuddas, A.; Coghill, D.R.; Banaschewski, T.; Soutullo, C.; Lynes, A.; Hodgkins, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 French ⚖ 64 KB

Efficacy and tolerability of lisdexamfet

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study

✍ Joseph Biederman; Suma Krishnan; Yuxin Zhang; James J. McGough; Robert L. Findli 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 953 KB

Health-Related Quality of Life and Funct

✍ Tobias Banaschewski, César Soutullo, Michel Lecendreux, Mats Johnson… 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 536 KB

Self-Reported quality of life in adults

Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study

✍ Adler, Lenard A. (author);Dirks, Bryan (author);Deas, Patrick (author);Raychaudh 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 399 KB

Self-Reported quality of life in adults

✍ Adler, Lenard A. (author);Dirks, Bryan (author);Deas, Patrick (author);Raychaudh 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 399 KB

EPA-0666 – Long-term maintenance of effi

EPA-0666 – Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): double-blind, placebo-controlled, multicentre, phase 3 randomized withdrawal study

✍ Newcorn, J.; Harpin, V.; Huss, M.; Johnson, M.; Ramos-Quiroga, J.A.; Van Stralen 📂 Article 📅 2014 🏛 Elsevier Science 🌐 French ⚖ 74 KB